Selexis SA Announces Service Agreement with Swedish Orphan Biovitrum AB (Sobi)

Selexis Will Apply the SURE CHO-Mplus Libraries™ to Achieve OptimalExpression Results with a Difficult-to-Express Protein

Geneva, Switzerland, September 22, 2015 – Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks (RCBs) used for drug discovery to commercial manufacturing, announced today the signing of a Service Agreement with Swedish Orphan Biovitrum AB (Sobi), a leading biopharmaceutical company focused developing therapies and services for people living with rare diseases.

Under the agreement, Selexis will use the SURE CHO-Mplus Libraries to address issues with difficult-to-express proteins.

“With the application of our new technologies, we are pleased to help Sobi reach their protein expression goal,” said Marco Bocci, PhD, vice president of business development and licensing of Selexis. “Our recent efforts in deciphering our CHO-M cell line is making a footprint in helping biopharmaceutical companies with advancing difficult-to-express proteins into the clinic and ultimately the patient.”

# # #

FOR MORE INFORMATION

Web www.selexis.com

LinkedIn www.linkedin.com/company/selexis-sa

Twitter www.twitter.com/SelexisSA

Facebook www.facebook.com/SelexisSA